Cantor Fitzgerald Downgrades CRISPR Therapeutics to Neutral
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Eric Schmidt has downgraded CRISPR Therapeutics (NASDAQ:CRSP) from Overweight to Neutral.
October 17, 2023 | 1:21 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
CRISPR Therapeutics has been downgraded from Overweight to Neutral by Cantor Fitzgerald.
Analyst ratings often have a significant impact on stock prices. A downgrade from Overweight to Neutral suggests that the analyst sees less upside potential in the stock, which could lead to selling pressure and a potential decrease in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100